ALLO
Allogene Therapeutics, Inc. Common Stock
stockNASDAQ
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for "off-the-shelf" use in patients. this approach eliminates the need to create personalized therapy from a patient's own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.04 | 2026-11-06 | -19.36% | 4.338 |
| 1M | 1.29 | 2026-10-13 | -34.98% | 1.934 |
| 3M | 1.98 | 2026-08-13 | -57.64% | 1.975 |
| 6M | 2.33 | 2026-05-13 | -64.00% | 1.583 |
| 1Y | 1.20 | 2025-11-13 | -30.11% | 1.924 |
| 2Y | 2.72 | 2024-11-13 | -69.17% | — |
| 5Y | 19.26 | 2021-11-12 | -95.64% | 1.592 |
Allogene Therapeutics, Inc. Common Stock (NASDAQ:ALLO) stock price today is $0.84, and today's volume is 11,661,001. ALLO is up 1.415% today. The 30 day average volume is 9.42M. ALLO market cap is $290.58M with 346.47M shares outstanding.